CHAMPIONS ONCOLOGY, INC. financial data

Symbol
CSBR on Nasdaq
Location
Baltimore, MD
Fiscal year end
30 April
Latest financial report
10-Q - Q2 2025 - 15 Sep 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 90% % 40%
Debt-to-equity 784% %
Return On Equity 88% % -73%
Return On Assets 10% %
Operating Margin 5% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13,788,421 shares 1.4%
Common Stock, Shares, Outstanding 13,788,421 shares 1.4%
Entity Public Float $15,400,000 USD -30%
Common Stock, Value, Issued $14,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 13,788,414 shares 1.4%
Weighted Average Number of Shares Outstanding, Diluted 13,788,414 shares -1.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $56,878,000 USD 10%
Research and Development Expense $7,453,000 USD -9.2%
Selling and Marketing Expense $7,721,000 USD 9.6%
General and Administrative Expense $9,382,000 USD -12%
Operating Income (Loss) $2,697,000 USD -140%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $2,840,000 USD -134%
Income Tax Expense (Benefit) $82,000 USD -110%
Net Income (Loss) Attributable to Parent $2,952,000 USD -133%
Earnings Per Share, Basic 0 USD/shares -130%
Earnings Per Share, Diluted 0 USD/shares -133%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,325,000 USD 257%
Accounts Receivable, after Allowance for Credit Loss, Current $9,474,000 USD 4.9%
Assets, Current $21,014,000 USD 59%
Operating Lease, Right-of-Use Asset $4,771,000 USD -20%
Goodwill $335,000 USD 0%
Other Assets, Noncurrent $196,000 USD 5.9%
Assets $30,546,000 USD 23%
Accounts Payable, Current $4,845,000 USD -7.4%
Accrued Liabilities, Current $1,801,000 USD -14%
Contract with Customer, Liability, Current $14,430,000 USD 40%
Liabilities, Current $22,698,000 USD 18%
Operating Lease, Liability, Noncurrent $4,244,000 USD -26%
Other Liabilities, Noncurrent $66,000 USD -82%
Liabilities $27,008,000 USD 6.9%
Retained Earnings (Accumulated Deficit) $80,358,000 USD 3.5%
Stockholders' Equity Attributable to Parent $3,508,000 USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $3,538,000 USD
Liabilities and Equity $30,546,000 USD 23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $600,000 USD 93%
Net Cash Provided by (Used in) Financing Activities $14,000 USD 62%
Net Cash Provided by (Used in) Investing Activities $46,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 13,908,754 shares 1.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $540,000 USD 97%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,325,000 USD 257%
Deferred Tax Assets, Valuation Allowance $14,838,000 USD -18%
Deferred Tax Assets, Gross $14,838,000 USD -18%
Operating Lease, Liability $5,750,000 USD -19%
Payments to Acquire Property, Plant, and Equipment $46,000 USD
Lessee, Operating Lease, Liability, to be Paid $10,405,000 USD -22%
Property, Plant and Equipment, Gross $16,252,000 USD 0.87%
Operating Lease, Liability, Current $1,506,000 USD 10%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,871,000 USD -1.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,922,000 USD -0.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $4,655,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,391,000 USD -17%
Deferred Tax Assets, Operating Loss Carryforwards $8,248,000 USD -8.7%
Unrecognized Tax Benefits $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,392,000 USD -17%
Depreciation, Depletion and Amortization $1,509,000 USD -21%
Share-based Payment Arrangement, Expense $604,000 USD -37%